Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study
Cardiology Discovery · 2023
DOI: 10.1097/cd9.0000000000000065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiology Discovery, 2023. Verfasst von Xiaozeng Wang und 15 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
This study aimed to evaluate the major adverse cardiovascular and cerebrovascular events (MACCEs) and overall safety profile associated with iodixanol in Chinese patients undergoing percutaneous coronary intervention (PCI).
Methods
Patients at 30 centers in China registered in the OpenClinic v3.6 database from October 30, 2013, to October 7, 2015, were included in the study. The primary endpoint was in-hospital MACCEs including target lesion revascularization (TLR), stroke, stent thrombosis, cardiac death, and PCI-related myocardial infarction (MI) within 72 h post-PCI. Secondary endpoints were MACCEs from 72 h to 30 d post-PCI and other safety events within 30 d post-PCI.
Results
A total of 3,042 patients were enrolled. The incidence of MACCEs within 72 h post-PCI was 2.33% ( n = 71), including cardiac death (0.03%, n = 1) and PCI-related MI (2.30%, n = 70). The incidence of MACCEs from 72 h to 30 d post-PCI was 0.16% ( n = 5), including cardiac death (0.10%, n = 3), PCI-related MI (0.03%, n = 1), and TLR for stent thrombosis (0.03%, n = 1). The incidence of composite angiographic or procedural complications was 2.86% ( n = 87); 233 (7.86%) patients had results suggesting contrast-induced acute kidney injury.
Conclusions
These findings indicate that the use of iodixanol in Chinese patients undergoing PCI is associated with a low incidence of MACCEs, confirming its safety in this population.
Zitieren
APA
Wang, X., Ma, D., Li, T., Li, B., Su, X., Wu, Y., Du, Z., Ji, Z., Yang, P., Yang, B., Cao, X., Li, J., Hou, F., Cheng, Z., Xu, B., & Han, Y. (2023). Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study. Cardiology Discovery. https://doi.org/10.1097/cd9.0000000000000065
Vancouver
Wang X, Ma D, Li T, Li B, Su X, Wu Y, et al. Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study. Cardiology Discovery. 2023. doi:10.1097/cd9.0000000000000065
BibTeX
@article{Wang2023,
author = {Wang, Xiaozeng and Ma, Dengfeng and Li, Tianchang and Li, Bao and Su, Xi and Wu, Yanqing and Du, Zhimin and Ji, Zheng and Yang, Ping and Yang, Baisong and Cao, Xuebin and Li, Junxia and Hou, Fengxia and Cheng, Ziping and Xu, Banglong and Han, Yaling},
title = {Incidence of Major Adverse Cardiovascular and Cerebrovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention with Iodixanol: An Observational Postauthorization Study},
journal = {Cardiology Discovery},
year = {2023},
doi = {10.1097/cd9.0000000000000065}
}
EUVIMED